Audit Series on Anticoagulant Reversal in Trauma and Anticoagulant Associated Bleeding

Start date
End date

The Haematology and Trauma Working Group of the National Blood Transfusion Committee (NBTC) will launch the 2026 re‑audit on the reversal of anticoagulant‑associated bleeding on Tuesday 5 May. This follows the initial audit undertaken between 1 January and 31 March 2022, which explored organisational guidance and case management for DOAC and VKA‑associated bleeding in trauma settings.

You can review the 2022 audit report here: Review of Direct Oral Anti‑Coagulants (DOACs) and Warfarin Reversal in Trauma Patients.

Previews and test versions of the upcoming audit tools are available to support teams in preparing ahead of the launch.

Scope of the 2026 Re-Audit

Test hospital login: 7938

Participation and Data Collection

The audit will run from Tuesday 5 May to Wednesday 5 August.

Hospitals may contribute by either:

  • Submitting up to 30 consecutive eligible cases; or
  • Providing all eligible cases during the three‑month window.

We encourage Hospital Transfusion Teams to liaise with their Heads of A&E / ED to identify a colleague to assist with patient identification and data entry, particularly as junior doctors and nursing staff often require involvement in audit for training.

Preparing for Launch

Ahead of 5 May, Hospital Transfusion teams may find it helpful to:

  • Review the preview PDFs and test links
  • Identify a supporting colleague in A&E / ED

Contact details for Hospital Sign-Ups

To support timely responses, please direct queries, and sign‑ups according to the day of the week:

Kind regards, 

Fatts Chowdhury

Consultant Haematologist in Transfusion Medicine

Chair NBTC Haematology & Trauma Group and Emergency Planning Working Group

Sasha Tidy

Operations Manager

National Blood Transfusion Committee